Interlink provides Januvia pre-launch med ed

Share this article:
Interlink Healthcare Communications will provide pre-launch medical education for Merck's Januvia (sitagliptin), a DPP-4 inhibitor for treating type II diabetes. Januvia is expected to be decided on by the FDA in October.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.